Date: 2015-04-23
Type of information: Collaboration agreement
Compound: MX-ICP technology
Company: Horizon Discovery (UK) Transgenomic (USA - NE)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On April 23, 2015, Horizon Discovery Group, the international life science company supplying research tools and services that power genomics research and the development of personalized medicines, and Transgenomic, a global biotechnology company advancing personalized medicine in cardiology, oncology and inherited diseases through advanced diagnostic tests and clinical and research services, announced a new Original Equipment Manufacture (OEM) agreement to incorporate Horizon’s human genomic reference standards, produced by Horizon’s Diagnostics division, into Transgenomic’s Multiplexed ICE COLD-PCR™ (MX-ICP) kits for use in research and clinical applications. Further details of the agreement were not disclosed. This agreement follows a collaborative project initiated last year between Horizon’s Diagnostics division and Transgenomic, which explored the utility of Horizon’s advanced reference standards in Transgenomic’s in vitro DNA mutation enrichment kits. The standards are being used in both quality control and mutation concentration assays.
Transgenomic’s MX-ICP technology offers major advantages for users of current sequencing technologies by delivering a sensitivity improvement of at least 100-fold in comparison to standard methodologies and enriching both known and previously unknown genetic alterations using a single multiplexed assay. The ultra-high sensitivity of MX-ICP makes it feasible to conduct comprehensive genomic analyses using either tissue biopsies or liquid samples such as blood or urine.
Financial terms:
Latest news:
